Tapering bDMARDs in axial SpA — what is the current evidence?

Tapering bDMARDs in axial SpA — what is the current evidence?Tapering bDMARDs in axial SpA — what is the current evidence?, Published online: 22 March 2019; doi:10.1038/s41584-019-0201-2Biologic DMARDs are a cornerstone treatment for severe axial spondyloarthritis. Although indications for treatment initiation are well codified, the timing and modalities for tapering remain unclear, despite medical and economic concerns. Encouraging data about treatment tapering are emerging that might guide future management strategies.

Source: Nature Reviews Rheumatology - March 21, 2019 Category: Rheumatology Authors: Nelly R. Ziade Xenofon Baraliakos Source Type: research